Skip to main content
European Commission logo print header

The anoikis suppressor TrKB as a target for novel anti-cancer agents

Objective

The failure of anti-cancer therapies generally results from locally intractable invasive growth or from the presence of metastases refractory to treatment with curative intent. A novel therapeutic strategy is to develop new anti-cancer drugs specifically targeting the invasive or metastatic phenotype of tumour cells.
We propose to validate at the preclinical level a strategy that targets the critical mechanism allowing apoptosis evasion and survival of invasive or metastatic tumour cells. Anoikis is a process by which a cell detached from its resident tissue undergoes apoptosis as a result of loss of normal cell-matrix interactions. Loss of anoikis allows survival of cancer cells in abnormal microenvironments, such as tissue compartments invaded by the primary tumour, and the intravascular compartment during the metastatic process. Participant 2 has recently discovered that the BDNF receptor TrkB is a potent suppressor of anoikis and is responsible for apoptosis evasion that occurs in aggressive human tumours overexpressing TrkB (Douma et al., 2004). The aim of the present proposal is to validate TrkB as a target for new anticancer drugs, aiming to restore anoikis and thereby destroy the invasive and metastatic cancer cells. This validation will include the identification TrkB-expressing tumour cell lines amongst a collection of resected human cancers. Then, abrogation of TrkB mediated signalling will be achieved by either selective TrkB mRNA-targeting small interfering RNAs (RNAi) delivered by viral vectors, or by novel and potent small molecule inhibitors that will be designed and synthesized.
The efficacy of these tools will be assessed by using anoikis-sensitive cell models and xenograft mouse models, particularly orthotopic metastasis models derived from human tumours. The mechanisms of TrkB-dependent anoikis suppression will also be investigated in order to identify additional markers for invasive and metastatic capability and novel drug target

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Coordinator

INSTITUT DE RECHERCHE PIERRE FABRE
EU contribution
No data
Address
45, Place Abel Gance
BOULOGNE
France

See on map

Links
Total cost
No data

Participants (3)